Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period.

Autor: Woo PYM; Department of Neurosurgery, Kwong Wah Hospital, Hong Kong.; Hong Kong Neuro-Oncology Society, Hong Kong., Yau S; Hong Kong Neuro-Oncology Society, Hong Kong., Lam TC; Hong Kong Neuro-Oncology Society, Hong Kong.; Department of Clinical Oncology, The University of Hong Kong, Hong Kong., Pu JKS; Hong Kong Neuro-Oncology Society, Hong Kong.; Division of Neurosurgery, Department of Surgery, Queen Mary Hospital, Hong Kong., Li LF; Hong Kong Neuro-Oncology Society, Hong Kong., Lui LCY; Hong Kong Neuro-Oncology Society, Hong Kong.; Department of Clinical Oncology, Princess Margaret Hospital, Hong Kong., Chan DTM; Division of Neurosurgery, Department of Surgery, Prince of Wales Hospital, Hong Kong, China., Loong HHF; Hong Kong Neuro-Oncology Society, Hong Kong.; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China., Lee MWY; Hong Kong Neuro-Oncology Society, Hong Kong.; Department of Neurosurgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China., Yeung R; Hong Kong Neuro-Oncology Society, Hong Kong.; Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China., Kwok CCH; Hong Kong Neuro-Oncology Society, Hong Kong.; Department of Clinical Oncology, Princess Margaret Hospital, Hong Kong., Au SK; Hong Kong Neuro-Oncology Society, Hong Kong., Tan TC; Hong Kong Neuro-Oncology Society, Hong Kong., Kan ANC; Hong Kong Neuro-Oncology Society, Hong Kong.; Department of Anatomical Pathology, Hong Kong Children's Hospital, Hong Kong, China., Chan TKT; Hong Kong Neuro-Oncology Society, Hong Kong.; Department of Neurosurgery, Princess Margaret Hospital, Hong Kong, China., Mak CHK; Hong Kong Neuro-Oncology Society, Hong Kong.; Department of Neurosurgery, Queen Elizabeth Hospital, Hong Kong, China., Mak HKF; Hong Kong Neuro-Oncology Society, Hong Kong.; Department of Diagnostic Radiology, The University of Hong Kong, Hong Kong, China., Ho JMK; Hong Kong Neuro-Oncology Society, Hong Kong.; Department of Neurosurgery, Tuen Mun Hospital, Hong Kong., Cheung KM; Hong Kong Neuro-Oncology Society, Hong Kong.; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China., Tse TPK; Department of Neurosurgery, Princess Margaret Hospital, Hong Kong, China., Lau SSN; Division of Neurosurgery, Department of Surgery, Queen Mary Hospital, Hong Kong., Chow JSW; Department of Neurosurgery, Queen Elizabeth Hospital, Hong Kong, China., El-Helali A; Department of Clinical Oncology, The University of Hong Kong, Hong Kong., Ng HK; Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China., Poon WS; Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Jazyk: angličtina
Zdroj: Neuro-oncology practice [Neurooncol Pract] 2022 Sep 10; Vol. 10 (1), pp. 50-61. Date of Electronic Publication: 2022 Sep 10 (Print Publication: 2023).
DOI: 10.1093/nop/npac069
Abstrakt: Background: The aim of this study is to address the paucity of epidemiological data regarding the characteristics, treatment patterns and survival outcomes of Chinese glioblastoma patients.
Methods: This was a population-level study of Hong Kong adult ( > 18 years) Chinese patients with newly diagnosed histologically confirmed glioblastoma between 2006 and 2019. The age standardized incidence rate (ASIR), patient-, tumor- treatment-related characteristics, overall survival (OS) as well as its predictors were determined.
Results: One thousand and ten patients with a median follow-up of 10.0 months were reviewed. The ASIR of glioblastoma was 1.0 per 100 000 population with no significant change during the study period. The mean age was 57 + 14 years. The median OS was 10.6 months (IQR: 5.2-18.4). Independent predictors for survival were: Karnofsky performance score > 80 (adjusted OR: 0.8; 95% CI: 0.6-0.9), IDH-1 mutant (aOR: 0.7; 95% CI: 0.5-0.9) or MGMT methylated (aOR: 0.7; 95% CI: 0.5-0.8) glioblastomas, gross total resection (aOR: 0.8; 95% CI: 0.5-0.8) and temozolomide chemoradiotherapy (aOR 0.4; 95% CI: 0.3-0.6). Despite the significant increased administration of temozolomide chemoradiotherapy from 39% (127/326) of patients in 2006-2010 to 63% (227/356) in 2015-2019 ( P -value < .001), median OS did not improve (2006-2010: 10.3 months vs 2015-2019: 11.8 months) (OR: 1.1; 95% CI: 0.9-1.3).
Conclusions: The incidence of glioblastoma in the Chinese general population is low. We charted the development of neuro-oncological care of glioblastoma patients in Hong Kong during the temozolomide era. Although there was an increased adoption of temozolomide chemoradiotherapy, a corresponding improvement in survival was not observed.
(© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje